It was my pleasure to present GenEndeavor’s approach to developing an early-detection ovarian cancer screening test at the MedInvest Oncology Investor conference this week. Ovarian cancer is one of the most challenging cancers to detect, with one of the worst survival rates in advanced stages. What keeps us optimistic is the very promising results of our pilot studies that show a solution is possible. We remain hopeful that more research, awareness, and financial resources will be dedicated to the early detection of ovarian cancer to one day enable a screening test. For more details about our approach and how we might partner to accelerate our important work, please reach out to my colleague Amanda at amanda@genendeavor.com. And thank you to the MedInvest Oncology Investor conference team and Cooley for their hospitality and opportunity to present this week. #LifeSciences #OncologyInvesting #InnovationInHealthcare #ConferenceParticipation.